Clinical Trial Update: A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency [Phase 2]

View source ↗

Summary

Phase 2 study evaluating dose response and safety of the investigational drug PHA-794428 in adults with growth hormone deficiency; the trial was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• PHA-794428

Snippet

Sponsor: Pfizer | Conditions: Growth Hormone Deficiency | Phase 2 | Status: TERMINATED